Lunit announces strategic partnerships to advance AI in cancer diagnostics across Europe
Lunit (KRX:328130.KQ), a frontrunner in AI-powered solutions for cancer diagnostics and therapeutics, is marking a significant milestone in its expansion across Europe through two pivotal commercial agreements. The company has secured supply contracts with TeleDiag, the leading teleradiology group in France, and the central region branch of the Portuguese League Against Cancer (LPCC), signifying a major step forward in the integration of advanced AI technology in European healthcare systems for chest X-ray and breast cancer detection.
In France, Lunit’s partnership with TeleDiag, established in 2008 and now the largest teleradiology network in the country, represents a groundbreaking initiative. By integrating Lunit INSIGHT CXR, a CE-marked, AI-powered solution capable of detecting ten of the most prevalent lung abnormalities, including lung cancer, into TeleDiag’s operations, the collaboration aims to significantly enhance the precision and efficacy of lung disease diagnosis. With over 600 radiologists in its network, servicing more than 300 medical practices and annually screening over 600,000 patients, TeleDiag’s adoption of Lunit’s technology underscores a transformative leap in French medical diagnostics.
TeleDiag’s choice of Lunit followed a rigorous evaluation of various AI solutions for chest X-rays, with Lunit standing out due to its superior technical performance and comprehensive range of detectable findings.
Simultaneously, Lunit has formalized a supply agreement with LPCC’s central region branch in Portugal to implement its FDA-cleared and CE-marked AI solution for mammography analysis, Lunit INSIGHT MMG. LPCC, a reputable private, non-profit entity established in 1941 and overseeing the Portuguese National Breast Cancer Screening Program, plans to utilize Lunit INSIGHT MMG to analyze approximately 100,000 mammograms annually over the next three years.
LPCC’s decision to incorporate Lunit’s solution came after an extensive validation process using their own screening data, where Lunit showcased outstanding performance, demonstrating its capability to significantly contribute to the early detection of breast cancer.
Brandon Suh, CEO of Lunit, highlighted the company’s global mission, stating, “Last week, we announced new supply contracts in East and Southeast Asia. This week, we unveil our new collaboration with TeleDiag and the Portuguese League Against Cancer in Europe; we’re not just expanding our reach; we’re transforming diagnostics globally.” Suh emphasized Lunit’s dedication to delivering AI-powered cancer screening solutions directly to healthcare providers worldwide, aiming to improve patient outcomes and ensure broad access to cutting-edge diagnostics.
The strategic partnerships between Lunit, TeleDiag, and the Portuguese League Against Cancer mark a significant advancement in the utilization of AI for cancer diagnostics across Europe. These collaborations not only signify Lunit’s commitment to enhancing global healthcare through innovative technology but also set a new standard in the early detection and treatment of cancer. By leveraging Lunit’s AI-powered solutions, TeleDiag and LPCC are poised to revolutionize cancer diagnostics, offering more accurate, efficient, and accessible screening processes that promise to improve patient outcomes and pave the way for a future where AI plays a central role in healthcare.